Eisai to Present New Data from Oncology Portfolio Including Lenvima and Halaven at ASCO Annual Meeting

TOKYO, May 26, 2020 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that lenvatinib mesylate (an oral multi-targeted tyrosine kinase receptor inhibitor, brand name: Lenvima^®, hereinafter referred to as "lenvatinib") and eribulin mesylate (a halichondrin-class microtubule dynamics inhibitor, product name: Halaven^®, “eribulin”) will be presented at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program) from May 29 to 31, 2020.

Relevant materials will be available on demand via the ASCO website on May 29 (Eastern Time).

At this year’s conference, data on lenvatinib in combination with Merck & Co.’s anti-PD-1 antibody Keytruda will be presented.^®Final results of two studies on combination therapy with pembrolizumab. One is an oral presentation (Abstract No.: 5008) of the metastatic renal cell carcinoma cohort from Study 111/KEYNOTE-146, and the other is a poster discussion (Abstract No.: 4519) on the use of combination therapy as first-line treatment for unresectable hepatocellular carcinoma in Study 116/KEYNOTE-524.

This version discusses investigational compounds and research use of FDA-approved products. It is not intended to convey conclusions regarding efficacy and safety.

There is no guarantee that any investigational compounds and research uses of FDA-approved products will successfully complete clinical development or obtain FDA approval.

Eisai positions oncology as a key therapeutic area, aiming to discover revolutionary new drugs with the potential to cure cancer. Building on cutting-edge cancer research, Eisai will continue to pioneer innovations in new drug development, striving to further meet the diverse needs of cancer patients, their families, and healthcare professionals, thereby contributing to the enhancement of their well-being.